Tissue Repair Company is a subsidiary of Cardium Therapeutics, Inc. (NYSE Amex:CXM). The former already submitted a 510(K) premarket notification application to the United States of America’s Food & Drug Administration (FDA). The 510(K) submission was made to get the regulator’s approval to bring Excellagen™ into the market. According to the company, it contains favorable data from the second stage of the Phase 2 Matrix clinical trial – which the company had lately conducted. The submission includes information on both the ExcellagenXL™ and ExcellagenFX™ – two medical devices of the same product line. On December 3, 20009, Cardium announced that the FDA is expected to decide whether Excellagen could be marketed or not within March 3, 2010.

Both ExcellagenXL and ExcellagenFX contain topical gels – that are made of Type 1 collagen proteins. These gels help in healing skin wounds – such as second degree burns,